IOL Chemicals and Pharmaceuticals Limited is a pharmaceutical company. The Company is engaged in manufacturing and selling of organic chemicals and bulk drugs. It caters to both domestic and international markets. It operates through two segments: Chemicals and Drugs. The Chemicals segment produces and sells acetic anhydride, acetyl chloride, mono chloro acetic acid and iso butyl benzene. The Drugs segment produces and sells various active pharmaceutical ingredients (APIs), such as ibuprofen and metformin. Its operations include Bulk Drugs APIs and specialty industrial organic chemicals. Its APIs division includes manufacturing of Bulk Drugs, such as anti-inflammatory and anti-diabetic. Its Specialty Industrial Organic Chemicals division produces ethyl acetate from organic alcohol for use in a range of end products in markets, such as flexible packaging, pharmaceuticals, food processing, pesticides and paint industries. Its manufacturing facility is located in Barnala, Punjab.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.